Skip to main content

Novartis Opens Tropical Disease Institute in Singapore Biopolis

NEW YORK, July 5 (GenomeWeb News) - Novartis opened a tropical diseases research facility today in Singapore's Biopolis, which will initially focus on drug-resistant tuberculosis and dengue fever.

 

The Novartis Institute for Tropical Diseases, a joint venture of the Swiss pharmaceutical giant and the Singapore Economic Development board, has the goal of getting at least two vaccines into the clinic by 2008, and onto the market by 2013, Novartis said. The center will be funded with $162.2 million over the next eight years, according to Novartis.  

 

The institute first began operations last year. Over 70 scientists and 30 students are slated to be working at the institute by the end of 2004.

 

The drug discovery activities at the Novartis institute will involve development of screening assays and target discovery. Biopolis also houses a DNA sequencing facility.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.